Remifentanil Hydrochloride I · 1,536 days since initial FDA posting
Brand: REMIFENTANIL HYDROCHLORIDE
FDA lists Remifentanil Hydrochloride I as Active Shortage (Hikma Pharmaceuticals USA, Inc.).
Availability on file: Available
Remifentanil Hydrochloride Injection: Active Shortage
Available Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Remifentanil Hydrochloride Injection
- Manufacturer
- Hikma Pharmaceuticals USA, Inc.
- Dosage Form
- Injection
- Presentation
- Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)
- Package NDC
- 0143-9392-10
Status & Timeline
- Status
- Active Shortage
- Availability
- Available
- First Reported
- Jun 28, 2022
- Last Updated
- Mar 12, 2026
- Therapeutic Category
- Analgesia/Addiction
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Additional lots will be available. Product will be made available as it is released.
Nearby, Other Remifentanil Shortage Records
Remifentanil Hydrochloride Injection
Mylan Institutional, a Viatris Company
Injection
Remifentanil Hydrochloride Injection
Mylan Institutional, a Viatris Company
Injection
Remifentanil Hydrochloride Injection
Mylan Institutional, a Viatris Company
Injection
Remifentanil Hydrochloride Injection
Fresenius Kabi USA, LLC
Injection
Remifentanil Hydrochloride Injection
Fresenius Kabi USA, LLC
Injection
Remifentanil Hydrochloride Injection
Hikma Pharmaceuticals USA, Inc.
Injection
FDA reason on file: Additional lots will be available. General shortage guidance lives on the tracker hub.